<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516616</url>
  </required_header>
  <id_info>
    <org_study_id>2020-S112</org_study_id>
    <nct_id>NCT04516616</nct_id>
  </id_info>
  <brief_title>Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer</brief_title>
  <official_title>Study of Pd-1 Antibody in Combination With Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Obstetrics &amp; Gynecology Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Army Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is one of the major health problems for chinese women. Besides surgery and&#xD;
      radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many&#xD;
      studies. However, not all patients respond well to neoadjuvant chemotherapy. This is an&#xD;
      open-label, single-arm, multi-center clinical trial to evaluate whether PD-1 in combination&#xD;
      with neoadjuvant chemotherapy will achieve better objective response rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive therapy Q3W until evaluation of efficacy. The first cycle include&#xD;
      cisplatin and albumin-bound paclitaxel. A combination of anti-PD-1 antibody (SHR-1210) with&#xD;
      cisplatin and albumin-bound paclitaxel would be given in second and third cycles. Patients&#xD;
      who have demonstrated complete or partial tumour responses （CR/PR）will receive surgery and&#xD;
      receive postoperative adjuvant therapy in accordance with NCCN guideline. Patients who have&#xD;
      demonstrated stable disease or progressive disease （SD/PD）will receive concurrent&#xD;
      radiochemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>ORR is defined as the percentage of the participants in the ITT population who have a Complete Response or Partial Response. The ORR will be assessed by a blind independent central reviewer per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pathological response rate is defined as the percentage of the participants in the ITT population who have complete pathologic remission or the infiltration depth of cervical lesions was &lt; 3mm in histological examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the time from randomization to disease recurrence (including death from recurrence if it was the first manifestation of recurrence), death without recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival （OS）</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time from the date of randomization until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Uterine Cervical Neoplasm</condition>
  <condition>Uterine Cervical Cancer</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1 cycle of cisplatin and albumin-bound paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of PD-1 antibody combined neoadjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)</intervention_name>
    <description>PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with locally advanced (2019 FIGO staged IB3, IIA2 and IIB（tumor size&gt; 4cm) )&#xD;
             cervical cancer and had not received any treatment before.&#xD;
&#xD;
          2. Histologically confirmed squamous carcinoma, adenocarcinoma or adenosquamous carcinoma&#xD;
             of the cervix.&#xD;
&#xD;
          3. Pathological examination of the PD-L1 positive（Combined score Positive Score≥1）.&#xD;
&#xD;
          4. Females 18-65 years of age.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group score 0-1.&#xD;
&#xD;
          6. WBC≥3.5*10^9/L, NEU≥1.5*10^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normal&#xD;
             upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum&#xD;
             creatinine and blood urea nitrogen ≤the upper limit of normal value.&#xD;
&#xD;
          7. Well-compliance and willing to keep in touch.&#xD;
&#xD;
          8. Willing to participate in this study, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active or known or suspected autoimmune disease requires a system treatment as follows&#xD;
             but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid&#xD;
             dysfunction, asthma requiring intervention with bronchodilators.&#xD;
&#xD;
          2. HIV infection, active HBV/HCV.&#xD;
&#xD;
          3. Condition requiring systemic treatment with small doses of corticosteroids within 1&#xD;
             months or large doses of corticosteroids within 3 months prior to randomization.&#xD;
&#xD;
          4. Any primary malignancy within 5 years.&#xD;
&#xD;
          5. Participate in other drug clinical trials at the same time.&#xD;
&#xD;
          6. Pregnant or lactating female patients.&#xD;
&#xD;
          7. Comorbidity including but not limited to: heart diseases (grade III-IV cardiac&#xD;
             insufficiency (NYHA standard); central nervous system diseases or nonfunctional&#xD;
             behavior; hematological system diseases; liver or kidney malformation or history of&#xD;
             surgery.&#xD;
&#xD;
          8. Drug or alcohol abuse.&#xD;
&#xD;
          9. Unable or unwilling to sign informed consents.&#xD;
&#xD;
         10. Not eligible for the study judged by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ding Ma, M.D., PhD</last_name>
    <phone>0086-27-836268</phone>
    <email>dma@tjh.tjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ding Ma, M.D., PhD</last_name>
      <phone>0086-27-8362681</phone>
      <email>dma@tjh.tjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Ding Ma</investigator_full_name>
    <investigator_title>Director of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

